Dr. Olek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
701 Gateway Blvd
Suite 420
South San Francisco, CA 94080- Is this information wrong?
Education & Training
- Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1991 - 1994
- Philadelphia College of Osteopathic MedicineClass of 1991
Certifications & Licensure
- MA State License 1994 - 2025
- VA State License 1992 - 2024
- PA State License 1987 - 1998
Clinical Trials
- An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment Start of enrollment: 2008 May 01
Publications & Presentations
PubMed
- 66 citationsOvercoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinibEzra Y. Rosen, Melissa Lynne Johnson, Sarah E. Clifford, Romel Somwar, Jennifer Kherani, Jieun Son, Arrien A. Bertram, Monika A. Davare, Eric Gladstone, Elena Ivanova,...> ;Clinical Cancer Research. 2021 Jan 1
- 5 citationsThe calcium-sensing receptor: A novel target for treatment and prophylaxis of neratinib-induced diarrhea.Taras Lysyy, Alshad S. Lalani, Elizabeth A. Olek, Irmina Diala, John P. Geibel> ;Pharmacology Research & Perspectives. 2019 Sep 13
- 9 citationsTargeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model.Kate R. Secombe, Imogen A. Ball, Joseph Shirren, Anthony Wignall, John W. Finnie, Dorothy M. K. Keefe, Francesca Avogadri-Connors, Elizabeth Olek, David Martin, Susan ...> ;Cancer Chemotherapy and Pharmacology. 2019 Mar 1
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: